Bellicum (BLCM) Alert: Johnson Fistel Announces Filing of Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc.; Encourages Investors to Contact the Firm

SAN DIEGO, March 1, 2018 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) ("Bellicum") on behalf of all purchasers of common stock during the period between May 8, 2017 and January 30, 2018, inclusive (the "Class Period"). Bellicum focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders.

If you wish to serve as a lead plaintiff, you must move the Court no later than April 9, 2018. If you wish to discuss this action, have any questions concerning this notice, or your rights or interests, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If you email, please include your phone number.  Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice or may choose to do nothing and remain an absent class member.

The complaint alleges that during the Class Period, defendants made false and misleading statements and failed to disclose adverse information. Specifically, defendants made false and misleading statements and failed to disclose that: (1) a substantial undisclosed risk of encephalopathy was associated with the Company's lead product candidate BPX-501; and (2) as a result, Bellicum's public statements were materially false and misleading at all relevant times.

On January 30, 2018, after the market closed, Bellicum issued a press release announcing that it had ''received notice from the U.S. Food and Drug Administration that U.S. studies of BPX-501 have been placed on a clinical hold following three cases of encephalopathy deemed as possibly related to BPX-501.''

On this news, the price of Bellicum stock declined nearly 26%, on January 31, 2018.

Plaintiff seeks to recover damages on behalf of all purchasers of Bellicum common stock during the Class Period. 

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com

View original content:http://www.prnewswire.com/news-releases/bellicum-blcm-alert-johnson-fistel-announces-filing-of-class-action-lawsuit-against-bellicum-pharmaceuticals-inc-encourages-investors-to-contact-the-firm-300606624.html

SOURCE Johnson Fistel, LLP